Systemic immune responses are associated with molecular characteristics of circulating tumor cells in head and neck squamous cell carcinoma.
circulating immune cells
circulating tumor cell
head and neck squamous cell carcinoma
molecular characteristics
systemic immunity
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
22
01
2021
accepted:
21
04
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
ppublish
Résumé
Systemic immunity mediated by circulating immune cells may affect clinical features, as well as the characteristics of circulating tumor cells (CTCs) in patients with head and neck squamous cell carcinoma (HNSCC). The present study aimed to analyze the influence of circulating immune cells, using their markers, on clinical features to investigate the association between systemic immunity and the molecular characteristics of CTCs. Circulating immune-cell markers were associated with disease progression and clinical outcomes in patients with HNSCC. Meanwhile, there was no significant association between the presence of CTCs and systemic immune-related markers. Moreover, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a expression in CTCs was significantly associated with higher lymphocyte counts (P=0.035) and an increased prognostic nutrition index (P=0.0157). Patients with CTCs expressing
Identifiants
pubmed: 34094545
doi: 10.3892/mco.2021.2309
pii: MCO-0-0-02309
pmc: PMC8165702
doi:
Types de publication
Journal Article
Langues
eng
Pagination
147Informations de copyright
Copyright © 2020, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Head Neck. 2019 Jun;41(6):1880-1888
pubmed: 30636187
J Immunol. 1998 Aug 15;161(4):1853-9
pubmed: 9712053
Oncotarget. 2014 Sep 30;5(18):8147-60
pubmed: 25230070
Nature. 1997 Mar 13;386(6621):181-6
pubmed: 9062191
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
J Transl Med. 2018 Dec 18;16(1):365
pubmed: 30563540
Int J Mol Sci. 2015 Feb 04;16(2):3391-404
pubmed: 25658794
Int J Environ Res Public Health. 2020 Mar 07;17(5):
pubmed: 32155982
Oncotarget. 2017 Aug 2;8(39):66075-66086
pubmed: 29029493
Curr Opin Oncol. 2006 Jan;18(1):77-82
pubmed: 16357568
Cancer Med. 2019 Mar;8(3):1004-1012
pubmed: 30693666
J Cancer. 2016 Jun 03;7(9):1095-104
pubmed: 27326253
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Oral Oncol. 2020 Mar;102:104558
pubmed: 32044652
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):89-102
pubmed: 31202687
Clin Dev Immunol. 2012;2012:656340
pubmed: 22611421
Br J Cancer. 2015 Mar 17;112(6):1088-97
pubmed: 25688736
Asian Pac J Cancer Prev. ;18(8):2227-2231
pubmed: 28843260
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32303612
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
Expert Opin Ther Targets. 2005 Aug;9(4):769-90
pubmed: 16083342
Cancer Immunol Immunother. 2014 Jan;63(1):45-57
pubmed: 24100804
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
Lab Invest. 2016 Sep;96(9):994-1003
pubmed: 27322955
PLoS One. 2013;8(3):e59321
pubmed: 23555017
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Crit Rev Oncol Hematol. 2018 Dec;132:130-137
pubmed: 30447918
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Oral Oncol. 2018 Apr;79:55-63
pubmed: 29598951
Mol Oncol. 2020 Jan;14(1):139-158
pubmed: 31600013
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
J Immunother Cancer. 2017 Oct 17;5(1):79
pubmed: 29037250
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Nihon Geka Gakkai Zasshi. 1984 Sep;85(9):1001-5
pubmed: 6438478
Cell Res. 2020 Jun;30(6):507-519
pubmed: 32467593
Dis Markers. 2017;2017:5727815
pubmed: 29434410
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Trends Cell Biol. 2009 Feb;19(2):72-80
pubmed: 19144521
J Clin Invest. 2019 May 21;129(8):3264-3276
pubmed: 31112530